Hydroxychloroquine to Increase Tumor Suppressor PAR-4 Levels in Oligometastatic Prostate Cancer

PHASE2CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

December 3, 2019

Primary Completion Date

March 8, 2024

Study Completion Date

March 8, 2024

Conditions

Prostate Cancer Recurrent

Interventions

DRUG

Hydroxychloroquine Sulfate 200Mg Tab

Twice daily for 90-days, administered two weeks prior to radiation/surgery of oligometastatic lesions

Trial Locations (1)

Markey Cancer Center - University of Kentucky, Lexington

All Listed Sponsors

lead

Patrick Hensley

OTHER

NCT04011410 - Hydroxychloroquine to Increase Tumor Suppressor PAR-4 Levels in Oligometastatic Prostate Cancer | Biotech Hunter | Biotech Hunter